clinical trial · NCT05094336
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
Amgen·phase2·active not recruiting·n = 329
Advanced MTAP-null Solid TumorsAnvumetostatDocetaxelComparator Anvumetostat Test Tablet
brief summary
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.
started
Feb 1, 2022
primary completion
May 27, 2026
completion
May 29, 2028
last updated
Mar 31, 2026
official title
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol